These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15373778)

  • 1. BRAF kinase gene V599E mutation in growing melanocytic lesions.
    Loewe R; Kittler H; Fischer G; Faé I; Wolff K; Petzelbauer P
    J Invest Dermatol; 2004 Oct; 123(4):733-6. PubMed ID: 15373778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
    Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA
    J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutations are common somatic events in melanocytic nevi.
    Kumar R; Angelini S; Snellman E; Hemminki K
    J Invest Dermatol; 2004 Feb; 122(2):342-8. PubMed ID: 15009715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin.
    Uribe P; Wistuba II; González S
    Am J Dermatopathol; 2003 Oct; 25(5):365-70. PubMed ID: 14501284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF point mutations in primary melanoma show different prevalences by subtype.
    Sasaki Y; Niu C; Makino R; Kudo C; Sun C; Watanabe H; Matsunaga J; Takahashi K; Tagami H; Aiba S; Horii A
    J Invest Dermatol; 2004 Jul; 123(1):177-83. PubMed ID: 15191558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
    Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
    Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
    Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
    Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
    Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma.
    Mihic-Probst D; Perren A; Schmid S; Saremaslani P; Komminoth P; Heitz PU
    Anticancer Res; 2004; 24(4):2415-8. PubMed ID: 15330192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.
    Mochel MC; Hammond MR; Frederick DT; Alora-Palli MB; Piris A; Flaherty KT; Hoang MP
    J Am Acad Dermatol; 2015 Sep; 73(3):491-9.e2. PubMed ID: 26190239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of constitutively active V599EBRaf.
    Andersen MH; Fensterle J; Ugurel S; Reker S; Houben R; Guldberg P; Berger TG; Schadendorf D; Trefzer U; Bröcker EB; Straten Pt; Rapp UR; Becker JC
    Cancer Res; 2004 Aug; 64(15):5456-60. PubMed ID: 15289355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF as a melanoma susceptibility candidate gene?
    Laud K; Kannengiesser C; Avril MF; Chompret A; Stoppa-Lyonnet D; Desjardins L; Eychene A; Demenais F; Lenoir GM; Bressac-de Paillerets B;
    Cancer Res; 2003 Jun; 63(12):3061-5. PubMed ID: 12810628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandem BRAF mutations in primary invasive melanomas.
    Thomas NE; Alexander A; Edmiston SN; Parrish E; Millikan RC; Berwick M; Groben P; Ollila DW; Mattingly D; Conway K
    J Invest Dermatol; 2004 May; 122(5):1245-50. PubMed ID: 15140228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T1799A BRAF mutations in conjunctival melanocytic lesions.
    Goldenberg-Cohen N; Cohen Y; Rosenbaum E; Herscovici Z; Chowers I; Weinberger D; Pe'er J; Sidransky D
    Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3027-30. PubMed ID: 16123397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanocytic nevi and melanoma: unraveling a complex relationship.
    Damsky WE; Bosenberg M
    Oncogene; 2017 Oct; 36(42):5771-5792. PubMed ID: 28604751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients.
    Kanitakis J; Baldassini S; Lora V; Euvrard S
    Eur J Dermatol; 2010; 20(2):167-71. PubMed ID: 19919912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of V599E BRAF mutations in desmoplastic melanomas.
    Davison JM; Rosenbaum E; Barrett TL; Goldenberg D; Hoque MO; Sidransky D; Westra WH
    Cancer; 2005 Feb; 103(4):788-92. PubMed ID: 15641040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.